Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ages 21 to 75 inclusive. Female subjects must be of non-childbearing potential;~* Has at the Screening Visit a serum uric acid ≥ 6 mg/dL, with or without a history of gout;~* The use of allopurinol, febuxostat (Uloric®), or probenecid as uric acid-lowering therapy is permissible if dosing has been stable for at least the month prior to the Screening Visit~* Has adequate venous access and able to receive IV therapy;~* Evidence of a personally signed and dated informed consent document indicating that subject has been informed of all pertinent aspects of the study;~Exclusion Criteria:~* Prior exposure to any experimental or marketed uricase;~* History of any allergy to pegylated products,~* Glucose-6-phosphate dehydrogenase deficiency or known catalase deficiency;~* History of hematological or autoimmune disorders, is immunosuppressed or immunocompromised;~* Has participated in a clinical trial within 30 days of the Screening;

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SEL-037 (pegsiticase) (Type: EXPERIMENTAL): Pegylated uricase

Based on this trial design, predict the completion outcome and termination type (if applicable).